Buy GRAL by Oct 9, 2029.

I am trying to ensure I diversity a bit into opportunities that are not just AI driven. $GRAL stock price IMO is ahead of itself in short term b/c of a favorable FDA advisory committee outcome last month that looks like it will clear the path for FDA approval early 2027. But looking at the potential over 3-4 years - this company could be doing 10mm recurring tests in 2030 annually and 5X+ the current market cap. * The Nancy …